{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T17:04:09Z","timestamp":1773162249498,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,8,13]],"date-time":"2018-08-13T00:00:00Z","timestamp":1534118400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s00280-018-3665-x","type":"journal-article","created":{"date-parts":[[2018,8,13]],"date-time":"2018-08-13T14:14:51Z","timestamp":1534169691000},"page":"795-802","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["In vitro UGT1A1 inhibition by tyrosine kinase inhibitors and association with drug-induced hyperbilirubinemia"],"prefix":"10.1007","volume":"82","author":[{"given":"Hisham","family":"Qosa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittany R.","family":"Avaritt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil R.","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna A.","family":"Volpe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,13]]},"reference":[{"key":"3665_CR1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ctrv.2012.09.004","volume":"39","author":"YL Teo","year":"2013","unstructured":"Teo YL, Ho HK, Chan A (2013) Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis. Cancer Treat Rev 39:199\u2013206","journal-title":"Cancer Treat Rev"},{"key":"3665_CR2","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s40264-013-0048-4","volume":"36","author":"RR Shah","year":"2013","unstructured":"Shah RR, Morganroth J, Shah DR (2013) Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf 36:491\u2013503","journal-title":"Drug Saf"},{"key":"3665_CR3","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1111\/bcp.12231","volume":"77","author":"R Iacovelli","year":"2013","unstructured":"Iacovelli R, Palazzo A, Procopio G, Santoni M, Trenta P, De Benedetto A, Mezi S, Cortesi E (2013) Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy. Br J Clin Pharmacol 77:929\u2013938","journal-title":"Br J Clin Pharmacol"},{"issue":"15_suppl","key":"3665_CR4","doi-asserted-by":"crossref","first-page":"9094","DOI":"10.1200\/jco.2013.31.15_suppl.9094","volume":"31","author":"A Daud","year":"2013","unstructured":"Daud A, Kluger HM, Edelman G, Gordon MS, Schimmoller F, Weitzman A, Samuel TS, Moussa AH, Flaherty K, Shapiro G (2013) Activity of cabozantinib in metastatic uveal melanoma: updated results from a phase II randomized discontinuation trial (RDT). J Clin Oncol 31(15_suppl):9094","journal-title":"J Clin Oncol"},{"key":"3665_CR5","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1158\/1078-0432.CCR-12-3041","volume":"19","author":"AX Zhu","year":"2013","unstructured":"Zhu AX, Ancukiewicz M, Supko JG, Sahani DV, Blaszkowsky LS, Meyerhardt JA, Abrams TA, McCleary NJ, Bhargava P, Muzikansky A, Sheehan S, Regan E, Vasudev E, Knowles M, Fuchs CS, Ryan DP, Jain RK, Duda DG (2013) Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study. Clin Cancer Res 19:1557\u20131566","journal-title":"Clin Cancer Res"},{"key":"3665_CR6","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1200\/JCO.2007.11.6210","volume":"25","author":"AA Miller","year":"2007","unstructured":"Miller AA, Murry DJ, Owzar K, Hollis DR, Lewis LD, Kindler HL, Marshall JL, Villalona-Calero MA, Edelman MJ, Hohl RJ, Lichtman SM, Ratain MJ (2007) Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol 25:3055\u20133060","journal-title":"J Clin Oncol"},{"key":"3665_CR7","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1200\/JCO.2007.11.0304","volume":"26","author":"RK Ramanathan","year":"2008","unstructured":"Ramanathan RK, Egorin MJ, Takimoto CH, Remick SC, Doroshow JH, LoRusso PA, Mulkerin DL, Grem JL, Hamilton A, Murgo AJ, Potter DM, Belani CP, Hayes MJ, Peng B, Ivy SP, National Cancer Institute Organ Dysfunction Working Group (2008) Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol 26:563\u2013569","journal-title":"J Clin Oncol"},{"key":"3665_CR8","doi-asserted-by":"publisher","first-page":"e62543","DOI":"10.1371\/journal.pone.0062543","volume":"8","author":"J Stebbing","year":"2013","unstructured":"Stebbing J, Payne R, Reise J, Frampton AE, Avery M, Woodley L, Di Leo A, Pestrin M, Krell J, Coombes RC (2013) The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study. PLoS ONE 8:e62543","journal-title":"PLoS ONE"},{"key":"3665_CR9","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa055104","volume":"354","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Giles F, Wunderle L, Bhalla K, O\u2019Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354:2542\u20132551","journal-title":"N Engl J Med"},{"key":"3665_CR10","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1158\/1078-0432.CCR-12-3214","volume":"19","author":"DL Mulkerin","year":"2013","unstructured":"Mulkerin DL, Belani CP, Gandhi L, Lau SC, Ivy SP, Newman EM (2013) Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res 19:3631\u20133639","journal-title":"Clin Cancer Res"},{"key":"3665_CR11","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1016\/j.ejca.2013.05.028","volume":"49","author":"J Bruix","year":"2013","unstructured":"Bruix J, Tak WY, Gasbarrini A, Santoro A, Colombo M, Lim HY, Mazzaferro V, Wiest R, Reig M, Wagner A, Bolondi L (2013) Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study. Eur J Cancer 49:3412\u20133419","journal-title":"Eur J Cancer"},{"key":"3665_CR12","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s10637-015-0237-3","volume":"33","author":"S Ogasawara","year":"2015","unstructured":"Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Saito T, Motoyama T, Suzuki E, Tawada A, Kanai F, Yokosuka O (2015) Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. Invest New Drugs 33:729\u2013739","journal-title":"Invest New Drugs"},{"key":"3665_CR13","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1200\/JCO.2015.63.2497","volume":"33","author":"S Kopetz","year":"2015","unstructured":"Kopetz S, Desai J, Chan E, Hecht JR, O\u2019Dwyer PJ, Maru D, Morris V, Janku F, Dasari A, Chung W, Issa J-PJ, Gibbs P, James B, Powis G, Nolop KB, Bhattacharya S, Saltz L (2015) Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J Clin Oncol 33:4032\u20134038","journal-title":"J Clin Oncol"},{"key":"3665_CR14","unstructured":"Drugs@FDA. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/"},{"key":"3665_CR15","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/1098-1004(200010)16:4<297::AID-HUMU2>3.0.CO;2-Z","volume":"16","author":"A Kadakol","year":"2000","unstructured":"Kadakol A, Ghosh SS, Sappal BS, Sharma G, Chowdhury JR, Chowdhury NR (2000) Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype. Hum Mutat 16:297\u2013306","journal-title":"Hum Mutat"},{"key":"3665_CR16","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1080\/03602530802341133","volume":"40","author":"YM Ah","year":"2008","unstructured":"Ah YM, Kim YM, Kim MJ, Choi YH, Park KH, Son IJ, Kim SG (2008) Drug-induced hyperbilirubinemia and the clinical influencing factors. Drug Metab Rev 40:511\u2013537","journal-title":"Drug Metab Rev"},{"key":"3665_CR17","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1124\/dmd.105.005447","volume":"33","author":"D Zhang","year":"2005","unstructured":"Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG (2005) In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 33:1729\u20131739","journal-title":"Drug Metab Dispos"},{"key":"3665_CR18","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1182\/blood.V126.23.2795.2795","volume":"126","author":"J Bahk","year":"2015","unstructured":"Bahk J, Claudiani S, Szydlo RM, Toma S, Abdillah F, Hing S, Deplano S, Milojkovic D, Apperley JF, Foroni L (2015) The association of Gilbert\u2019s syndrome with hyperbilirubinaemia occurring on any of imatinib, dasatinib and nilotinib in patients with chronic myeloid leukaemia (CML). Blood 126:2795","journal-title":"Blood"},{"key":"3665_CR19","first-page":"551","volume":"29","author":"MW Saif","year":"2016","unstructured":"Saif MW, Smith MH, Maloney A, Diasio RB (2016) Imatinib-induced hyperbilirubinemia with UGT1A1 (28) promoter polymorphism: first case series in patients with gastrointestinal stromal tumor. Ann Gastroenterol 29:551\u2013556","journal-title":"Ann Gastroenterol"},{"key":"3665_CR20","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/clpt.2011.277","volume":"91","author":"CF Spraggs","year":"2012","unstructured":"Spraggs CF, Parham LR, Hunt CM, Dollery CT (2012) Lapatinib-induced liver injury characterized by class II HLA and Gilbert\u2019s syndrome genotypes. Clin Pharmacol Ther 91:647\u2013652","journal-title":"Clin Pharmacol Ther"},{"key":"3665_CR21","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1038\/sj.leu.2404827","volume":"21","author":"JB Singer","year":"2007","unstructured":"Singer JB, Shou Y, Giles F, Kantarjian HM, Hsu Y, Robeva AS, Rae P, Weitzman A, Meyer JM, Dugan M, Ottmann OG (2007) UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia 21:2311\u20132315","journal-title":"Leukemia"},{"key":"3665_CR22","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/sj.bjc.6605653","volume":"102","author":"CF Xu","year":"2010","unstructured":"Xu CF, Reck BH, Xue Z, Huang L, Baker KL, Chen M, Chen EP, Ellens HE, Mooser VE, Cardon LR, Spraggs CF, Pandite L (2010) Pazopanib-induced hyperbilirubinemia is associated with Gilbert\u2019s syndrome UGT1A1 polymorphism. Br J Cancer 102:1371\u20131377","journal-title":"Br J Cancer"},{"key":"3665_CR23","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1093\/annonc\/mdt394","volume":"24","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Johnson T, Choueiri TK, Deen KC, Xue Z, Pandite LN, Carpenter C, Xu CF (2013) Hyperbilirubinemia in pazopanib or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms. Ann Oncol 24:2927\u20132928","journal-title":"Ann Oncol"},{"issue":"suppl. 3","key":"3665_CR24","doi-asserted-by":"publisher","first-page":"S391","DOI":"10.1016\/S0959-8049(16)31095-4","volume":"51","author":"T Wakatsuki","year":"2015","unstructured":"Wakatsuki T, Suenaga M, Shinozaki E, Nagayama S, Nakayama I, Matsushima T, Ogura M, Ichimura T, Takahari D, Chin K, Kumekawa Y, Sato Y, Fukunaga Y, Ueno M, Mizunuma N, Yamaguchi T (2015) Genetic variants of UGT1A1 and 1A9 could be associated with regorafenib induced toxicity in Japanese patients with metastatic colorectal cancer. Eur J Cancer 51(suppl. 3):S391","journal-title":"Eur J Cancer"},{"key":"3665_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00280-009-1096-4","volume":"65","author":"J Meza-Junco","year":"2009","unstructured":"Meza-Junco J, Chu QS, Christensen O, Rajagopalan P, Das S, Stefanyschyn R, Sawyer MB (2009) UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib. Cancer Chemother Pharmacol 65:1\u20134","journal-title":"Cancer Chemother Pharmacol"},{"key":"3665_CR26","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1007\/s00216-009-3441-1","volume":"396","author":"TM Donato","year":"2010","unstructured":"Donato TM, Montero S, Castell JV, Gomez-Lechon J, Lahoz MJ A (2010) Validated assay for studying activity profiles of human liver UGTs after drug exposure: inhibition and induction studies. Anal Bioanal Chem 396:2251\u20132263","journal-title":"Anal Bioanal Chem"},{"key":"3665_CR27","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1124\/dmd.110.035030","volume":"39","author":"J Zhou","year":"2011","unstructured":"Zhou J, Tracy TS, Remmel RP (2011) Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates\/inhibitors. Drug Metab Dispos 39:322\u2013329","journal-title":"Drug Metab Dispos"},{"key":"3665_CR28","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1016\/S0043-1354(03)00239-2","volume":"37","author":"Y Yoon","year":"2003","unstructured":"Yoon Y, Westerhoff P, Snyder SA, Esparza M (2003) HPLC-fluorescence detection and adsorption of bisphenol A, 17\u03b2-estradiol, and 17\u03b1-ethynyl estradiol on powdered activated carbon. Water Res 37:3530\u20133537","journal-title":"Water Res"},{"key":"3665_CR29","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3109\/00498254.2013.820006","volume":"44","author":"WJ Chiou","year":"2014","unstructured":"Chiou WJ, De Morais SM, Kikuchi R, Voorman RL, Li X, Bow DAJ (2014) In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia. Xenobiotica 44:276\u2013282","journal-title":"Xenobiotica"},{"key":"3665_CR30","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrd3028","volume":"9","author":"KM Giacomini","year":"2010","unstructured":"Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215\u2013236","journal-title":"Nat Rev Drug Discov"},{"key":"3665_CR31","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/pds.885","volume":"12","author":"JS Almenoff","year":"2003","unstructured":"Almenoff JS, DuMouchel W, Kindman LA, Yang X, Fram D (2003) Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting. Pharmacoepidemiol Drug Saf 12:517\u2013521","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3665_CR32","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1124\/dmd.107.017806","volume":"35","author":"D Zhang","year":"2007","unstructured":"Zhang D, Zhang D, Cui D, Gambardella J, Ma L, Barros A, Wang L, Fu Y, Rahematpura S, Nielsen J, Donegan M, Zhang H, Humphreys WG (2007) Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism. Drug Metab Dispos 35:2270\u20132280","journal-title":"Drug Metab Dispos"},{"key":"3665_CR33","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1021\/mp4001348","volume":"10","author":"JH Chang","year":"2013","unstructured":"Chang JH, Plise E, Cheong J, Ho Q, Lin M (2013) Evaluating the in vitro inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in predicting drug-induced hyperbilirubinemia. Mol Pharm 10:3067\u20133075","journal-title":"Mol Pharm"},{"key":"3665_CR34","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00280-010-1445-3","volume":"67","author":"K Fujita","year":"2011","unstructured":"Fujita K, Sugiyama M, Akiyama Y, Ando Y, Sasaki Y (2011) The small-molecule tyrosine kinase inhibitor nilotinib is a potent noncompetitive inhibitor of the SN-38 glucuronidation by human UGT1A1. Cancer Chemother Pharmacol 67:237\u2013241","journal-title":"Cancer Chemother Pharmacol"},{"key":"3665_CR35","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/j.1365-2125.2011.03911.x","volume":"71","author":"Y Lui","year":"2011","unstructured":"Lui Y, Ram\u00edrez J, Ratain MJ (2011) Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors. Br J Clin Pharmacol 71:917\u2013920","journal-title":"Br J Clin Pharmacol"},{"key":"3665_CR36","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.cbi.2004.08.008","volume":"150","author":"SD Campbell","year":"2004","unstructured":"Campbell SD, de Morais SM, Xu JJ (2004) Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. Chem Biol Interact 150:179\u2013187","journal-title":"Chem Biol Interact"},{"key":"3665_CR37","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/clpt.2013.74","volume":"94","author":"KM Hillgren","year":"2013","unstructured":"Hillgren KM, Keppler D, Zur AA, Giacomini KM, Stieger B, Cass CE, Zhang L, International Transporter Consortium (2013) Emerging transporters of clinical importance: an update from the International Transporter Consortium. Clin Pharmacol Ther 94:52\u201363","journal-title":"Clin Pharmacol Ther"},{"key":"3665_CR38","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1124\/dmd.113.055772","volume":"42","author":"D Keppler","year":"2014","unstructured":"Keppler D (2014) The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia. Drug Metab Dispos 42:561\u2013565","journal-title":"Drug Metab Dispos"},{"key":"3665_CR39","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/toxsci\/kft176","volume":"136","author":"RE Morgan","year":"2013","unstructured":"Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK (2013) A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci 136:216\u2013241","journal-title":"Toxicol Sci"},{"key":"3665_CR40","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1124\/dmd.109.031302","volume":"38","author":"M Dohse","year":"2010","unstructured":"Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, Bates SE (2010) Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos 38:1371\u20131380","journal-title":"Drug Metab Dispos"},{"key":"3665_CR41","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/bjc.2013.811","volume":"110","author":"S Hu","year":"2014","unstructured":"Hu S, Mathijssen RH, de Bruijn P, Baker SD, Sparreboom A (2014) Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations. Br J Cancer 110:894\u2013898","journal-title":"Br J Cancer"},{"key":"3665_CR42","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1515\/dmdi-2014-0014","volume":"29","author":"V Khurana","year":"2014","unstructured":"Khurana V, Minocha M, Pal D, Mitra AK (2014) Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors. Drug Metab Drug Interact 29:249\u2013259","journal-title":"Drug Metab Drug Interact"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-018-3665-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3665-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3665-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T05:32:29Z","timestamp":1720503149000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-018-3665-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,13]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["3665"],"URL":"https:\/\/doi.org\/10.1007\/s00280-018-3665-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,13]]},"assertion":[{"value":"17 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All the authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}